deltatrials
Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07387848

Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas (GLO-PACT)

A Phase II,Open Label, Single Arm, Multicenter Study Investigating the Efficacy and Safety of Glofitamab When Used as a Bridge to and/or Consolidation Post-transplant for Patients With Relapsed/Refractory B-cell Lymphomas Transformed Low Grade B Cell Lymphoma) Fit and Eligible for ASCT

Sponsor: American University of Beirut Medical Center

Conditions Diffuse Large B Cell Lymphoma Refractory
Interventions Glofitamab
Updated 1 time since 2026 Last updated: Jan 30, 2026 Started: Apr 15, 2026 Primary completion: Dec 15, 2031 Completion: Dec 15, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diffuse Large B Cell Lymphoma Refractory and is currently actively recruiting participants. American University of Beirut Medical Center leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2026 – present · 6 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • American University of Beirut Medical Center
  • Roche Pharma AG
Data source: American University of Beirut Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.